NSCLC Patient

Antigen presentation by tumor infiltrating B cells influences CD4 T cell phenotype and function in primary lung cancer patient tumors
Tullia Bruno, Peggy Ebner, Brandon Moore, Daniel Munson, John Mitchell, Jeffrey Kern, Dario AA Vignali, Jill Slansky

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P397; DOI: 10.1186/2051-1426-3-S2-P397
TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study
Elisabeth Quoix, Lecia Sequist, John Nemunaitis, Thaddeus Beck, Piotr Jaskiewicz, Jean-Philippe Oster, Arnaud Scherpereel, Erzsébet Juhász, Zsuzsanna Mark, Rosa Alvarez, Saiama Waqar, Joseph Potz, Nandagopal Vrindavanam, Anton Melnyk, Helen Ross, Jean-Marc Limacher

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) O12; DOI: 10.1186/2051-1426-2-S3-O12
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
Tetsuro Sasada, Teppei Yamada, Koichi Azuma, Satoko Matsueda, Kyogo Itoh

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P235; DOI: 10.1186/2051-1426-1-S1-P235
P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
HM Specht, J Pelzel, H Hautmann, RM Huber, B Schossow, M Molls, G Multhoff

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P41; DOI: 10.1186/2051-1426-2-S2-P41

Log in using your username and password

Main menu

Log in using your username and password

You are here

NSCLC Patient